NASDAQ: SLRNAcelyrin Inc Stock
$2.47+0.02 (+0.82%)
Updated Apr 30, 2025
SLRN Price
$2.47
Fair Value Price
$0.68
Market Cap
$248.75M
52 Week Low
$1.85
52 Week High
$7.25
P/E
-0.99x
P/B
0.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$248.23M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$304M
Beta
0.89
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SLRN Overview
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SLRN's potential to beat the market
- SLRN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SLRN
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important SLRN news, forecast changes, insider trades & much more!
SLRN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLRN ($2.47) is overvalued by 262.72% relative to our estimate of its Fair Value price of $0.68 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLRN ($2.47) is not significantly undervalued (262.72%) relative to our estimate of its Fair Value price of $0.68 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLRN due diligence checks available for Premium users.
Valuation
SLRN fair value
Fair Value of SLRN stock based on Discounted Cash Flow (DCF)
Price
$2.47
Fair Value
$0.68
Overvalued by
262.72%
SLRN ($2.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLRN ($2.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.99x
Industry
-162.28x
Market
29.18x
SLRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.54x
Industry
4.45x
SLRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLRN's financial health
Profit margin
Revenue
$0.0
Net Income
-$79.0M
Profit Margin
0%
SLRN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$491.1M
Liabilities
$32.8M
Debt to equity
0.07
SLRN's short-term assets ($480.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLRN's short-term assets ($480.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$121.6M
Investing
-$22.7M
Financing
$1.9M
SLRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLRN vs Biotech Stocks
Acelyrin Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.